Johnson & Johnson Showcases Positive AFib Data, Treatment Results

Johnson & Johnson (NYSE:JNJ) reported new cardiovascular data at the 2025 European Society of Cardiology Congress.

In the VARIPURE substudy of the SECURE trial, the company's VARIPULSE Platform for pulsed field ablation in atrial fibrillation showed 99.7% acute effectiveness, no strokes, and a 0.6% adverse event rate among 791 patients.

The system integrates with J&J's CARTO 3 mapping platform to improve efficiency and workflow. ...